Log in to your Inderes Free account to see all free content on this page.

ALK-Abelló

213.80 DKK

-0.93 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-0.93 %

+2.10 %

-6.72 %

-6.47 %

+2.10 %

+47.55 %

+94.36 %

+73.96 %

+519.71 %

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Market cap

47.64B DKK

Turnover

43.84M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

5.5.

2026

Interim report Q1'26

20.8.

2026

Interim report Q2'26

18.11.

2026

Interim report Q3'26

All

Press releases

ShowingAll content types

Press release19 hours ago

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

Regulatory press release4/8/2026, 8:37 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Regulatory press release4/1/2026, 8:05 AM

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release3/31/2026, 7:01 AM

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

Regulatory press release3/16/2026, 5:37 PM

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

Press release3/4/2026, 10:20 AM

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors

Regulatory press release2/20/2026, 1:54 PM

Annual General Meeting in ALK-Abelló A/S on 16 March 2026

Regulatory press release2/20/2026, 6:31 AM

Henriette Mersebach to step down as ALK’s head of R&D

Regulatory press release2/20/2026, 6:17 AM

Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin

Press release2/13/2026, 11:16 AM

Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026

Regulatory press release1/29/2026, 3:15 PM

ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children

Press release1/8/2026, 4:17 PM

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

Press release12/22/2025, 3:13 PM

ALK – Financial calendar for the 2026 financial year

Regulatory press release12/19/2025, 9:46 PM

Major shareholder announcement

Regulatory press release12/1/2025, 2:35 PM

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

Regulatory press release11/12/2025, 4:22 PM

Nine-month interim report (Q3) 2025 (unaudited)

Regulatory press release11/12/2025, 4:16 PM

ALK upgrades its full-year outlook

Press release11/6/2025, 4:01 PM

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

Regulatory press release9/17/2025, 7:44 AM

ALK and GenSci partner to expand the AIT market in China

Press release9/8/2025, 12:21 PM

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.